

doi:10.1038/mt.2015.163

Erratum to “A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis”

Kin-Mei Leung, Sarah Batey, Robert Rowlands, Samine J Isaac, Phil Jones, Victoria Drewett, Joana Carvalho, Miguel Gaspar, Sarah Weller, Melanie Medcalf, Mateusz M Wydro, Robert Pegram, Geert C Mudde, Anton Bauer, Kevin Moulder, Max Woisetschläger, Mihriban Tuna, John S Haurum and Haijun Sun

Molecular Therapy (2015) **23**: 1722–1733. doi:10.1038/mt.2015.127

The top western blot analysis of figure 5b was incorrectly labeled as pHER2. It should read HER2. The publisher apologizes for the error.

doi:10.1038/mt.2015.186

Corrigendum to “Disruption of K_{ATP} Channel Expression in Skeletal Muscle by Targeted Oligonucleotide Delivery Promotes Activity-linked Thermogenesis”

Siva Rama Krishna Koganti, Zhiyong Zhu, Ekaterina Subbotina, Zhan Gao, Ana Sierra, Manuel Proenza, Liping Yang, Alexey Alekseev, Denice Hodgson-Zingman and Leonid Zingman

Molecular Therapy (2015) **23**: 707–716. doi:10.1038/mt.2015.21

In the Materials and Methods section under “Vivo-morpholino,” the amount of oligonucleotides was incorrectly described as 2 nmol/l in 50 μ l normal saline (about 1 ng). The correct amount is 2 nmol in 50 μ l normal saline (approximately 20 μ g), split between 2-3 injections per muscle. The authors regret the error.